|
1
|
Jemal A, Bray F, Center MM, Ferlay vvJ,
Ward E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Holmes RS and Vaughan TL: Epidemiology and
pathogenesis of esophageal cancer. Semin Radiat Oncol. 17:2–9.
2007. View Article : Google Scholar
|
|
3
|
Lin Y, Totsuka Y, He Y, Kikuchi S, Qiao Y,
Ueda J, Wei W, Inoue M and Tanaka H: Epidemiology of esophageal
cancer in Japan and China. J Epidemiol. 23:233–242. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wu KS, Huo X and Zhu GH: Relationships
between esophageal cancer and spatial environment factors by using
Geographic Information System. Sci Total Environ. 393:219–225.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tran GD, Sun XD, Abnet CC, Fan JH, Dawsey
SM, Dong ZW, Mark SD, Qiao YL and Taylor PR: Prospective study of
risk factors for esophageal and gastric cancers in the Linxian
general population trial cohort in China. Int J Cancer.
113:456–463. 2005. View Article : Google Scholar
|
|
6
|
Muñoz N, Crespi M, Grassi A, Qing WC,
Qiong S and Cai LZ: Precursor lesions of oesophageal cancer in
high-risk populations in Iran and China. Lancet. 1:876–879. 1982.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Blot WJ, Li JY, Taylor PR, Guo W, Dawsey
SM and Li B: The Linxian trials: Mortality rates by vitamin-mineral
intervention group. Am J Clin Nutr. 62(Suppl): 1424S–1426S.
1995.PubMed/NCBI
|
|
8
|
Jemal A, Center MM, DeSantis C and Ward
EM: Global patterns of cancer incidence and mortality rates and
trends. Cancer Epidemiol Biomarkers Prev. 19:1893–1907. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chen CP, Braunstein S, Mourad M, Hsu IC,
Haas-Kogen D, Roach M III and Fogh SE: Quality improvement of
International Classification of Diseases, 9th revision, diagnosis
coding in radiation oncology: Single-institution prospective study
at University of California, San Francisco. Pract Radiat Oncol.
5:e45–e51. 2015. View Article : Google Scholar
|
|
10
|
Macefield RC, Avery KN and Blazeby JM:
Integration of clinical and patient-reported outcomes in surgical
oncology. Br J Surg. 100:28–37. 2013. View
Article : Google Scholar
|
|
11
|
Daly JM, Fry WA, Little AG, Winchester DP,
McKee RF, Stewart AK and Fremgen AM: Esophageal cancer: Results of
an American College of Surgeons Patient Care Evaluation Study. J Am
Coll Surg. 190:562–573. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Enzinger PC and Mayer RJ: Esophageal
cancer. N Engl J Med. 349:2241–2252. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lepage C, Rachet B, Jooste V, Faivre J and
Coleman MP: Continuing rapid increase in esophageal adenocarcinoma
in England and Wales. Am J Gastroenterol. 103:2694–2699. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Pohl H and Welch HG: The role of
overdiagnosis and reclassification in the marked increase of
esophageal adenocarcinoma incidence. J Natl Cancer Inst.
97:142–146. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kranzfelder M, Büchler P and Friess H:
Surgery within multimodal therapy concepts for esophageal squamous
cell carcinoma (ESCC): the MRI approach and review of the
literature. Adv Med Sci. 54:158–169. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lightdale CJ; American College of
Gastroenterology: Esophageal cancer. Am J Gastroenterol. 94:20–29.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Iizuka T, Isono K, Kakegawa T and Watanabe
H; Japanese Committee for Registration of Esophageal Carcinoma
Cases: Parameters linked to ten-year survival in Japan of resected
esophageal carcinoma. Chest. 96:1005–1011. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Toh Y, Egashira A and Yamamoto M:
Epigenetic alterations and their clinical implications in
esophageal squamous cell carcinoma. Gen Thorac Cardiovasc Surg.
61:262–269. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Shang L and Wang M: Molecular alterations
and clinical relevance in esophageal squamous cell carcinoma. Front
Med. 7:401–410. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Takeno S, Yamashita S, Takahashi Y, Ono K,
Kamei M, Moroga T and Kawahara K: Survivin expression in
oesophageal squamous cell carcinoma: Its prognostic impact and
splice variant expression. Eur J Cardiothorac Surg. 37:440–445.
2010.
|
|
21
|
Akyürek N, Memiş L, Ekinci O, Köktürk N
and Oztürk C: Survivin expression in pre-invasive lesions and
non-small cell lung carcinoma. Virchows Arch. 449:164–170. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Altieri DC: Validating survivin as a
cancer therapeutic target. Nat Rev Cancer. 3:46–54. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yang X, Xiong G, Chen X, Xu X, Wang K, Fu
Y, Yang K and Bai Y: Polymorphisms of survivin promoter are
associated with risk of esophageal squamous cell carcinoma. J
Cancer Res Clin Oncol. 135:1341–1349. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kato J, Kuwabara Y, Mitani M, Shinoda N,
Sato A, Toyama T, Mitsui A, Nishiwaki T, Moriyama S, Kudo J and
Fujii Y: Expression of survivin in esophageal cancer: Correlation
with the prognosis and response to chemotherapy. Int J Cancer.
95:92–95. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ikeguchi M and Kaibara N: Survivin
messenger RNA expression is a good prognostic biomarker for
oesophageal carcinoma. Br J Cancer. 87:883–887. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Grabowski P, Kühnel T, Mühr-Wilkenshoff F,
Heine B, Stein H, Höpfner M, Germer CT and Scherübl H: Prognostic
value of nuclear survivin expression in oesophageal squamous cell
carcinoma. Br J Cancer. 88:115–119. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Dabrowski A, Filip A, Zgodziński W,
Dabrowska M, Polańska D, Wójcik M, Zinkiewicz K and Wallner G:
Assessment of prognostic significance of cytoplasmic survivin
expression in advanced oesophageal cancer. Folia Histochem
Cytobiol. 42:169–172. 2004.PubMed/NCBI
|
|
28
|
Mita AC, Mita MM, Nawrocki ST and Giles
FJ: Survivin: Key regulator of mitosis and apoptosis and novel
target for cancer therapeutics. Clin Cancer Res. 14:5000–5005.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li C, Li Z, Zhu M, Zhao T, Chen L, Ji W,
Chen H and Su C: Clinicopathological and prognostic significance of
survivin over-expression in patients with esophageal squamous cell
carcinoma: A meta-analysis. PLoS One. 7:e447642012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Altieri DC: Survivin, cancer networks and
pathway-directed drug discovery. Nat Rev Cancer. 8:61–70. 2008.
View Article : Google Scholar
|
|
31
|
Altieri DC: Survivin and IAP proteins in
cell-death mechanisms. Biochem J. 430:199–205. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kanwar JR, Kamalapuram SK and Kanwar RK:
Targeting survivin in cancer: The cell-signalling perspective. Drug
Discov Today. 16:485–494. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ryan BM, O'Donovan N and Duffy MJ:
Survivin: A new target for anti-cancer therapy. Cancer Treat Rev.
35:553–562. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Saito T, Hama S, Izumi H, Yamasaki F,
Kajiwara Y, Matsuura S, Morishima K, Hidaka T, Shrestha P, Sugiyama
K and Kurisu K: Centrosome amplification induced by survivin
suppression enhances both chromosome instability and
radiosensitivity in glioma cells. Br J Cancer. 98:345–355. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Sharma H, Sen S, Lo Muzio L, Mariggiò A
and Singh N: Antisense-mediated downregulation of anti-apoptotic
proteins induces apoptosis and sensitizes head and neck squamous
cell carcinoma cells to chemotherapy. Cancer Biol Ther. 4:720–727.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Islam A, Kageyama H, Takada N, Kawamoto T,
Takayasu H, Isogai E, Ohira M, Hashizume K, Kobayashi H, Kaneko Y
and Nakagawara A: High expression of Survivin, mapped to 17q25, is
significantly associated with poor prognostic factors and promotes
cell survival in human neuroblastoma. Oncogene. 19:617–623. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hattori M, Sakamoto H, Satoh K and
Yamamoto T: DNA demethylase is expressed in ovarian cancers and the
expression correlates with demethylation of CpG sites in the
promoter region of c-erbB-2 and survivin genes. Cancer Lett.
169:155–164. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Li F and Altieri DC: Transcriptional
analysis of human survivin gene expression. Biochem J. 344:305–311.
1999.PubMed/NCBI
|
|
39
|
Kawakami H, Tomita M, Matsuda T, Ohta T,
Tanaka Y, Fujii M, Hatano M, Tokuhisa T and Mori N: Transcriptional
activation of survivin through the NF-kappaB pathway by human
T-cell leukemia virus type I tax. Int J Cancer. 115:967–974. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Schreck R, Albermann K and Baeuerle PA:
Nuclear factor kappa B: An oxidative stress-responsive
transcription factor of eukaryotic cells (a review). Free Radic Res
Commun. 17:221–237. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Takizawa BT, Uchio EM, Cohen JJ, Wheeler
MA and Weiss RM: Downregulation of survivin is associated with
reductions in TNF receptors' mRNA and protein and alterations in
nuclear factor kappa B signaling in urothelial cancer cells. Cancer
Invest. 25:678–684. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Hayden MS and Ghosh S: Signaling to
NF-kappaB. Genes Dev. 18:2195–2224. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Sen R and Baltimore D: Inducibility of
kappa immunoglobulin enhancer-binding protein Nf-kappa B by a
posttranslational mechanism. Cell. 47:921–928. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Scheidereit C: IkappaB kinase complexes:
Gateways to NF-kappaB activation and transcription. Oncogene.
25:6685–6705. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Kim HJ, Hawke N and Baldwin AS: NF-kappaB
and IKK as therapeutic targets in cancer. Cell Death Differ.
13:738–747. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Karin M: NF-kappaB and cancer: Mechanisms
and targets. Mol Carcinog. 45:355–361. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Lin C, Song L, Gong H, Liu A, Lin X, Wu J,
Li M and Li J: Nkx2–8 downregulation promotes angiogenesis and
activates NF-κB in esophageal cancer. Cancer Res. 73:3638–3648.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Zhu H, Wang Q, Hu C, Zhang W, Quan L, Liu
M, Xu N and Xiao Z: High expression of survivin predicts poor
prognosis in esophageal squamous cell carcinoma following
radiotherapy. Tumour Biol. 32:1147–1153. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Cao M, Yie SM, Wu SM, Chen S, Lou B, He X,
Ye SR, Xie K, Rao L, Gao E and Ye NY: Detection of
survivin-expressing circulating cancer cells in the peripheral
blood of patients with esophageal squamous cell carcinoma and its
clinical significance. Clin Exp Metastasis. 26:751–758. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Debruyne PR, Witek M, Gong L, Birbe R,
Chervoneva I, Jin T, Domon-Cell C, Palazzo JP, Freund JN, Li P, et
al: Bile acids induce ectopic expression of intestinal guanylyl
cyclase C through nuclear factor-kappaB and Cdx2 in human
esophageal cells. Gastroenterology. 130:1191–1206. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Konturek PC, Nikiforuk A, Kania J, Raithel
M, Hahn EG and Mühldorfer S: Activation of NFkappaB represents the
central event in the neoplastic progression associated with
Barrett's esophagus: A possible link to the inflammation and
overexpression of COX-2, PPARgamma and growth factors. Dig Dis Sci.
49:1075–1083. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Kang MR, Kim MS, Kim SS, Ahn CH, Yoo NJ
and Lee SH: NF-kappaB signalling proteins p50/p105, p52/p100, RelA,
and IKKepsilon are over-expressed in oesophageal squamous cell
carcinomas. Pathology. 41:622–625. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Kausar T, Sharma R, Hasan MR, Tripathi SC,
Saraya A, Chattopadhyay TK, Gupta SD and Ralhan R: Clinical
significance of GPR56, transglutaminase 2, and NF-κB in esophageal
squamous cell carcinoma. Cancer Invest. 29:42–48. 2011. View Article : Google Scholar
|
|
54
|
Izzo JG, Malhotra U, Wu TT, Ensor J,
Luthra R, Lee JH, Swisher SG, Liao Z, Chao KS, Hittelman WN, et al:
Association of activated transcription factor nuclear factor kappab
with chemo-radiation resistance and poor outcome in esophageal
carcinoma. J Clin Oncol. 24:748–754. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Li B, Li YY, Tsao SW and Cheung AL:
Targeting NF-kappaB signaling pathway suppresses tumor growth,
angiogenesis, and metastasis of human esophageal cancer. Mol Cancer
Ther. 8:2635–2644. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Song L, Gong H, Lin C, Wang C, Liu L, Wu
J, Li M and Li J: Flotillin-1 promotes tumor necrosis factor-α
receptor signaling and activation of NF-κB in esophageal squamous
cell carcinoma cells. Gastroenterology. 143:995–1005. 2012.
View Article : Google Scholar
|
|
57
|
Tian F, Zhang C, Tian W, Jiang Y and Zhang
X: Comparison of the effect of p65 siRNA and curcumin in promoting
apoptosis in esophageal squamous cell carcinoma cells and in nude
mice. Oncol Rep. 28:232–240. 2012.PubMed/NCBI
|
|
58
|
Oeckinghaus A and Ghosh S: The NF-kappaB
family of transcription factors and its regulation. Cold Spring
Harb Perspect Biol. 1:a0000342009. View Article : Google Scholar
|
|
59
|
Sakurai H, Chiba H, Miyoshi H, Sugita T
and Toriumi W: IkappaB kinases phosphorylate NF-kappaB p65 subunit
on serine 536 in the transactivation domain. J Biol Chem.
274:30353–30356. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Hayden MS and Ghosh S: S hared principles
in NF-kappaB signaling. Cell. 132:344–362. 2008. View Article : Google Scholar : PubMed/NCBI
|
